Theolytics
Location: United Kingdom, England, Oxford
Total raised: $33.12M
Investors 5
| Date | Name | Website |
| 30.08.2022 | M Ventures | m-ventures... |
| - | Oxford Uni... | innovation... |
| 04.03.2021 | Taiho Vent... | taihoventu... |
| - | Oxford Sci... | oxfordscie... |
| - | Epidarex C... | epidarex.c... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 02.09.2024 | Grant | $2.63M | - |
| 17.04.2024 | - | $23.66M | - |
| 07.01.2021 | Series A | $6.83M | - |
Mentions in press and media 18
| Date | Title | Description |
| 03.09.2024 | Theolytics Secures £2M Grant to Revolutionize Ovarian Cancer Treatment | In a significant leap for cancer treatment, Theolytics has been awarded a £2 million grant from Innovate UK. This funding will propel the clinical development of THEO-260, a next-generation oncolytic viral therapy aimed at ovarian cancer. T... |
| 02.09.2024 | Theolytics Awarded Significant £2M Transforming Cancer Therapeutics Grant from Innovate UK | The funding will support Theolytics’ Phase 1 clinical trial for THEO-260 in ovarian cancer and incorporates comprehensive biomarker studies to showcase the candidate's differentiated dual tumour-lytic and immunotherapeutic mechanism of acti... |
| 02.09.2024 | Theolytics Awarded Significant £2M Transforming Cancer Therapeutics Grant from Innovate UK | The funding will support Theolytics’ Phase 1 clinical trial for THEO-260 in ovarian cancer and incorporates comprehensive biomarker studies to showcase the candidate's differentiated dual tumour-lytic and immunotherapeutic mechanism of acti... |
| 17.04.2024 | Sound Bioventures Joins Theolytics in Oncolytic Virus Financing | Sound Bioventures, a venture capital fund, invests in Theolytics, a UK biotechnology company, to advance THEO-260 in ovarian cancer trials. The funding round raised £19M ($24.5M) with strong international syndicate support. Theolytics aims ... |
| 17.04.2024 | Theolytics successfully closes latest financing raising total of £19M ($24.5M) and welcomes Sound Bioventures as new investor | Oxford, UK April 17th, 2024. Theolytics, a biotechnology company developing next-generation oncolytic viral therapies, today announced it has successfully closed its latest financing round, raising a total of £19M ($24.5M) with the addition... |
| 17.04.2024 | Sound Bioventures joins £19M ($24.5M) financing in UK oncolytic virus company Theolytics | Sound Bioventures joins strong international syndicate comprising M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises and the University of Oxford New funding enables Theolytics to advance lead candidate THEO-260 throug... |
| 17.04.2024 | Sound Bioventures joins £19M ($24.5M) financing in UK oncolytic virus company Theolytics | - |
| 17.04.2024 | Theolytics Closes £19M Funding Round | Theolytics, an Oxford, UK-based biotechnology company developing oncolytic viral therapies, raised £19M in funding. Backers included Sound Bioventures, which joined M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises an... |
| 17.04.2024 | Theolytics successfully closes latest financing raising total of £19M ($24.5M) and welcomes Sound Bioventures as new investor | - |
| 10.07.2021 | Theolytics Expands Series A Funding Round | Theolytics, an Oxford, UK-based deveoper of a library of potential adenovirus product candidates and breakthrough bioselection systems, raised new funding from M Ventures. M Ventures – the strategic venture capital arm of Merck – joined the... |
Show more